Predicting, managing and preventing new-onset diabetes after transplantation

Minerva Endocrinologica

Volumn 37, Issue 3, 2012, Pages 233-246

  Gosmanov, A R ^a   Dagogo Jack, S ^a  

^a UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

Author keywords

Immunosuppression; Kidney transplantation; Liver transplantation; Risk factors

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ATORVASTATIN; BELATACEPT; CYCLOSPORIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIPEPTIDYL PEPTIDASE IV INHIBITOR; FIBRIC ACID DERIVATIVE; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; GLUCOCORTICOID; GLUCOSE; HEMOGLOBIN A1C; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMMUNOSUPPRESSIVE AGENT; INSULIN; INSULIN SENSITIZING AGENT; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MAGNESIUM; MEVINOLIN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; RAPAMYCIN; ROSIGLITAZONE; SIMVASTATIN; SULFONYLUREA; TACROLIMUS; TRANSCRIPTION FACTOR 7 LIKE 2; TRIACYLGLYCEROL; UNINDEXED DRUG; VILDAGLIPTIN;

ADVERSE OUTCOME; BLOOD GLUCOSE MONITORING; BODY MASS; CARDIAC ALLOGRAFT VASCULOPATHY; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; COST EFFECTIVENESS ANALYSIS; DIABETES MELLITUS; DIABETIC PATIENT; DISEASE ASSOCIATION; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG MEGADOSE; DRUG WITHDRAWAL; DYSLIPIDEMIA; ETHNICITY; EXERCISE; FAMILY HISTORY; FLUID RETENTION; FRACTURE; GASTROINTESTINAL DISEASE; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; GLYCEMIC CONTROL; GRAFT FAILURE; GRAFT REJECTION; HEART TRANSPLANTATION; HEMOGLOBIN BLOOD LEVEL; HEPATITIS C; HOSPITAL DISCHARGE; HUMAN; HYPERCHOLESTEROLEMIA; HYPERGLYCEMIA; HYPERTENSION; HYPERTRIGLYCERIDEMIA; HYPOGLYCEMIA; IMPAIRED GLUCOSE TOLERANCE; INCIDENCE; INSULIN SENSITIVITY; INSULIN TREATMENT; INTESTINE MOTILITY; KIDNEY TRANSPLANTATION; LENGTH OF STAY; LIFESTYLE MODIFICATION; LIVER TRANSPLANTATION; LOW DRUG DOSE; LUNG TRANSPLANTATION; MAGNESIUM BLOOD LEVEL; MORBIDITY; NAUSEA; NEW ONSET DIABETES AFTER TRANSPLANTATION; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; ORAL GLUCOSE TOLERANCE TEST; POST TRANSPLANT HYPERTENSION; POSTOPERATIVE CARE; POSTOPERATIVE COMPLICATION; PREOPERATIVE PERIOD; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RHABDOMYOLYSIS; RISK FACTOR; SIDE EFFECT; SMOKING CESSATION; TRIACYLGLYCEROL BLOOD LEVEL; VOMITING; WEIGHT GAIN;

DIABETES MELLITUS; DIABETES MELLITUS, TYPE 2; DISEASE PROGRESSION; EVIDENCE-BASED MEDICINE; HEART TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INCIDENCE; KIDNEY TRANSPLANTATION; LIFE STYLE; LIVER TRANSPLANTATION; LUNG TRANSPLANTATION; ORGAN TRANSPLANTATION; PREDICTIVE VALUE OF TESTS; RISK FACTORS; TENNESSEE;

EID: 84867452607     PISSN: 03911977     EISSN: 18271634     Source Type: Journal    
DOI: None     Document Type: Review

References (100)

1. Lane JT, Dagogo-Jack S. Approach to the patient with new-onset diabetes after transplant (NODAT). J Clin Endocrinol Metab 2011;96:3289-97.
2. Pham PT, Pham PC, Lipshutz GS, Wilkinson AH. New onset diabetes mellitus after solid organ transplantation. Endocrinol Metab Clin North Am 2007; 36:873-90; vii.
3. Woodward RS, Schnitzler MA, Baty J, Lowell JA, Lopez-Rocafort L, Haider S et al. Incidence and cost of new onset diabetes mellitus among U.S. wait-listed and transplanted renal allograft recipients. Am J Transplant 2003; 3:590-8. (Pubitemid 36612842)
4. Christie JD, Edwards LB, Kucheryavaya AY, Benden C, Dobbels F, Kirk R et al. The Registry of the International Society for Heart and Lung Transplantation: Twenty-eighth Adult Lung and Heart-Lung Transplant Report-2011. J Heart Lung Transplant 2011;30:1104-22.
5. Kuo HT, Sampaio MS, Vincenti F, Bunnapradist S. Associations of pretransplant diabetes mellitus, newonset diabetes after transplant, and acute rejection with transplant outcomes: an analysis of the Organ Procurement and Transplant Network/United Network for Organ Sharing (OPTN/UNOS) database. Am J Kidney Dis 2010;56:1127-39.
6. Kuo HT, Sampaio MS, Ye X, Reddy P, Martin P, Bunnapradist S. Risk factors for new-onset diabetes mellitus in adult liver transplant recipients, an analysis of the Organ Procurement and Transplant Network/United Network for Organ Sharing database. Transplantation 2010;89:1134-40.
7. Ye X, Kuo HT, Sampaio MS, Jiang Y, Bunnapradist S. Risk factors for development of new-onset diabetes mellitus after transplant in adult lung transplant recipients. Clinical Transplantation 2011;25:885-91.
8. Ye X, Kuo HT, Sampaio MS, Jiang Y, Reddy P, Bunnapradist S. Risk factors for development of new-onset diabetes mellitus in adult heart transplant recipients. Transplantation 2010;89:1526-32.
9. Davidson JA, Wilkinson A. New-Onset Diabetes After Transplantation 2003 International Consensus Guidelines: an endocrinologist's view. Diabetes care 2004;27:805-12. (Pubitemid 38280557)
10. Wilkinson A, Davidson J, Dotta F, Home PD, Keown P, Kiberd B et al. Guidelines for the treatment and management of new-onset diabetes after transplantation. Clinical Transplantation 2005;19:291-8. (Pubitemid 40711959)
11. Cosio FG, Kudva Y, van der Velde M, Larson TS, Textor SC, Griffin MD et al. New onset hyperglycemia and diabetes are associated with increased cardiovascular risk after kidney transplantation. Kidney Int 2005;67:2415-21. (Pubitemid 41623405)
12. Davidson J, Wilkinson A, Dantal J, Dotta F, Haller H, Hernandez D et al. New-onset diabetes after transplantation: 2003 International consensus guidelines. Proceedings of an international expert panel meeting. Barcelona, Spain, 19 February 2003. Transplantation 2003;75:SS3-24.
13. Hjelmesaeth J, Hartmann A, Leivestad T, Holdaas H, Sagedal S, Olstad M et al. The impact of early-diagnosed new-onset post-transplantation diabetes mellitus on survival and major cardiac events. Kidney Int 2006;69:588-95. (Pubitemid 43164454)
14. Kasiske BL, Snyder JJ, Gilbertson D, Matas AJ. Diabetes mellitus after kidney transplantation in the United States. Am J Transplant 2003;3:178-85. (Pubitemid 36323115)
15. Ojo AO. Cardiovascular complications after renal transplantation and their prevention. Transplantation 2006;82:603-11. (Pubitemid 44403693)
16. Porrini E, Delgado P, Torres A. Metabolic syndrome, insulin resistance, and chronic allograft dysfunction. Kidney international 2010;S42-6.
17. John PR, Thuluvath PJ. Outcome of patients with new-onset diabetes mellitus after liver transplantation compared with those without diabetes mellitus. Liver Transpl 2002;8:708-13.
18. Moon JI, Barbeito R, Faradji RN, Gaynor JJ, Tzakis AG. Negative impact of new-onset diabetes mellitus on patient and graft survival after liver transplantation: Long-term follow up. Transplantation 2006,82:1625-8. (Pubitemid 46035640)
19. Ollech JE, Kramer MR, Peled N, Ollech A, Amital A, Medalion B et al. Post-transplant diabetes mellitus in lung transplant recipients: incidence and risk factors. Eur J Cardiothorac Surg 2008;33:844-8.
20. Valantine H. Cardiac allograft vasculopathy after heart transplantation: risk factors and management. J Heart Lung Transplant 2004;23.S187-93. (Pubitemid 38496395)
21. Marchetti P. New-onset diabetes after transplantation. J Heart Lung Transplant 2004;23:S194-201. (Pubitemid 38496396)
22. Pham PT, Pham PM, Pham SV, Pham PA, Pham PC. New onset diabetes after transplantation (NODAT): an overview. Diabetes Metab Syndr Obes 2011;4:175-86.
23. Subramanian S, Trence DL. Immunosuppressive agents: effects on glucose and lipid metabolism. Endocrinol Metab Clin North Am 2007; 36:891-905; vii.
24. Martinez-Castelao A, Hernandez MD, Pascual J, Morales JM, Mareen R, Errasti P et al. Detection and treatment of post kidney transplant hyperglycemia: a Spanish multicenter cross-sectional study. Transplant Proc 2005;37:3813-6. (Pubitemid 43015175)
25. Van Laecke S, Desideri F, Geerts A, Van Vlierberghe H, Berrevoet F, Rogiers X et al. Hypomagnesemia and the risk of new-onset diabetes after liver transplantation. Liver Transpl 2010;16:1278-87.
26. Van Laecke S, Van Biesen W, Verbeke F, De Bacquer D, Peeters P, Vanholder R. Posttransplantation hypomagnesemia and its relation with immunosuppression as predictors of new-onset diabetes after transplantation. Am J Transplant 2009;9:2140-9.
27. Madhav D, Ram R, Dakshinamurty KV. Posttransplant diabetes mellitus: analysis of risk factors, effects on biochemical parameters and graft function 5 years after renal transplantation. Transplant Proc 2010;42:4069-71.
28. Gane EJ. Diabetes mellitus following liver transplantation in patients with hepatitis C virus: risks and consequences. Am J Transplant 2012;12:531-8.
29. Perez MJ, Garcia DM, Taybi BJ, Daga JA, Rey JM, Grande RG et al. Cardiovascular risk factors after liver transplantation: analysis of related factors. Transplant Proc 2011;43:739-41.
30. Saliba F, Lakehal M, Pageaux GP, Roche B, Vanlemmens C, Duvoux C et al. Risk factors for new-onset diabetes mellitus following liver transplantation and impact of hepatitis C infection: an observational multiceńter study. Liver Transpl 2007;13:136-44. (Pubitemid 46099983)
31. Veldt BJ, Duarte-Rojo A, Thompson AJ, Watt KD, Heimbach JK, Tillmann HL et al. Recipient IL28B Polymorphism Is an Important Independent Predictor of Posttransplant Diabetes Mellitus in Liver Transplant Patients with Chronic Hepatitis C. Am J Transplant 2012;12:737-44.
32. Gelley F, Zadori G, Firneisz G, Wagner L, Fehervari I, Gerlei Z et al. Relationship between hepatitis C virus recurrence and de novo diabetes after liver transplantation: the Hungarian experience. Transplant Proc 2011;43:1281-2.
33. Hjelmesaeth J, Sagedal S, Hartmann A, Rollag H, Egeland T, Hagen M et al. Asymptomatic cytomegalovirus infection is associated with increased risk of new-onset diabetes mellitus and impaired insulin release after renal transplantation. Diabetologia 2004;47:1550-6. (Pubitemid 39371637)
34. Delgado-Borrego A, Liu YS, Jordan SH, Agrawal S, Zhang H, Christofi M et al. Prospective study of liver transplant recipients with HCV infection: evidence for a causal relationship between HCV and insulin resistance. Liver Transpl 2008;14:193-201. (Pubitemid 351267276)
35. Ghisdal L, Van Laecke S, Abramowicz MJ, Vanholder R, Abramowicz D. New-onset diabetes after renal transplantation: risk assessment and management. Diabetes Care 2012;35:181-8.
36. Hjelmesaeth J, Hartmann A, Kofstad J, Egeland T, Stenstrom J, Fauchald P. Tapering off prednisolone and cyclosporin the first year after renal transplantation: the effect on glucose tolerance. Nephrol Dial Transplant 2001;16:829-35. (Pubitemid 32257984)
37. Hjelmesaeth J, Hartmann A, Kofstad J, Stenstrom J, Leivestad T, Egeland T et al. Glucose intolerance after renal transplantation depends upon prednisolone dose and recipient age. Transplantation 1997;64.979-83.
38. Midtvedt K, Hjelmesaeth J, Hartmann A, Lund K, Paulsen D, Egeland T et al. Insulin resistance after renal transplantation: the effect of steroid dose reduction and withdrawal. J Am Soc Nephrol 2004;15:3233-9. (Pubitemid 39578856)
39. Abdelmannan D, Tahboub R, Genuth S, Ismail-Beigi F. Effect of dexamethasone on oral glucose tolerance in healthy adults. Endocr Pract 2010;16:770-7.
40. Clore JN, Thurby-Hay L. Glucocorticoid-induced hyperglycemia. Endocr Pract 2009;15:469-74.
41. Kauh EA, Mixson LA, Shankar S, McCarthy J, Maridakis V, Morrow L et al. Short-term metabolic effects of prednisone administration in healthy subjects. Diabetes Obes Metab 2011;13:1001-7.
42. Pagano G, Cavallo-Perin P, Cassader M, Bruno A, Ozzello A, Masciola P et al. An in vivo and in vitro study of the mechanism of prednisone-induced insulin resistance in healthy subjects. J Clin Invest 1983; 72:1814-20. (Pubitemid 14229061)
43. Rizza RA, Mandarino LJ, Gerich JE. Cortisol-induced insulin resistance in man: impaired suppression of glucose production and stimulation of glucose utilization due to a postreceptor detect of insulin action. J Clin Endocrinol Metab 1982;54:131-8. (Pubitemid 13242146)
44. Venkatesan N, Davidson MB, Hutchinson A. Possible role for the glucose-fatty acid cycle in dexamethasone-induced insulin antagonism in rats. Metabolism: Clinical and Experimental 1987;36:883-91. (Pubitemid 17135084)
45. Knoll GA, Bell RC. Tacrolimus versus cyclosporin for immunosuppression in renal transplantation: metaanalysis of randomised trials. BMJ 1999;318:1104-7. (Pubitemid 29192148)
46. Bloom RD, Rao V, Weng F, Grossman RA, Cohen D, Mange KC. Association of hepatitis C with posttransplant diabetes in renal transplant patients on tacrolimus. J Am Soc Nephrol 2002;13:1374-80. (Pubitemid 34441419)
47. Drachenberg CB, Klassen DK, Weir MR, Wiland A, Fink JC, Bartlett ST et al. Islet cell damage associated with tacrolimus and cyclosporine: morphological features in pancreas allograft biopsies and clinical correlation. Transplantation 1999;68:396-402. (Pubitemid 29384108)
48. Redmon JB, Olson LK, Armstrong MB, Greene MJ, Robertson RP. Effects of tacrolimus (FK506) on human insulin gene expression, insulin mRNA levels, and insulin secretion in HIT-T15 cells. J Clin Invest 1996; 98:2786-93. (Pubitemid 26427406)
49. Dieterle CD, Schmauss S, Veitenhansl M, Gutt B, Illner WD, Land W et al. Glucose metabolism after pancreas transplantation: cyclosporine versus tacrolimus. Transplantation 2004;77:1561-5. (Pubitemid 38703038)
50. Duijnhoven EM, Boots JM, Christiaans MH, Wolffenbuttel BH, Van Hooff JP. Influence of tacrolimus on glucose metabolism before and after renal transplantation: a prospective study. J Am Soc Nephrol 2001;12:583-8. (Pubitemid 32180028)
51. van Duijnhoven EM, Christiaans MH, Boots JM, Nieman FH, Wolffenbuttel BH, van Hooff JP. Glucose metabolism in the first 3 years after renal transplantation in patients receiving tacrolimus versus cyclosporine-based immunosuppression. J Am Soc Nephrol 2002;13.213-20.
52. KDIGO clinical practice guideline for the care of kidney transplant recipients. Am J Transplant 2009;9(Suppl 3):S1-155.
53. Rostaing L, Cantarovich D, Mourad G, Budde K, Rigotti P, Mariat C et al. Corticosteroid-free immunosuppression with tacrolimus, mycophenolate mofetil, and daclizumab induction in renal transplantation. Transplantation 2005;79:807-14. (Pubitemid 40546200)
54. Veroux M, Corona D, Giuffrida G, Gagliano M, Sorbello M, Virgilio C et al. New-onset diabetes mellitus after kidney transplantation: the role of immunosuppression. Transplant Proc 2008;40:1885-7.
55. Teutonico A, Schena PF, Di Paolo S. Glucose metabolism in renal transplant recipients: effect of calcineurin inhibitor withdrawal and conversion to sirolimus. J Am Soc Nephrol 2005;16:3128-35. (Pubitemid 44743511)
56. Johnston O, Rose CL, Webster AC, Gill JS. Sirolimus is associated with new-onset diabetes in kidney transplant recipients. J Am Soc Nephrol 2008;19:1411-8.
57. Flechner SM, Glyda M, Cockfield S, Grinyo J, Legendre C, Russ G et al. The ORION study: comparison of two sirolimus-based regimens versus tacrolimus and mycophenolate mofetil in renal allograft recipients. Am J Transplant 2011;11:1633-44.
58. Vodenik B, Rovira J, Campistol JM. Mammalian target of rapamycin and diabetes: what does the current evidence tell us? Transplant Proc 2009;41:S31-8.
59. Vivarelli M, Dazzi A, Cucchetti A, Gasbarrini A, Zanello M, Di Gioia P et al. Sirolimus in liver transplant recipients: a large single-center experience. Transplant Proc 2010;42:2579-84.
60. Klein CL, Brennan DC. The tradeoff between the risks of acute rejection and new-onset diabetes after kidney transplant. Am J Kidney Dis 2010;56:1026-8.
61. Woodle ES, First MR, Pirsch J, Shihab F, Gaber AO, Van Veldhuisen P. A prospective, randomized, double-blind, placebo-controlled multicenter trial comparing early (7 day) corticosteroid cessation versus long-term, low-dose corticosteroid therapy. Ann Surg 2008;248:564-77.
62. Aasebo W, Midtvedt K, Valderhaug TG, Leivestad T, Hartmann A, Reisaeter AV et al. Impaired glucose homeostasis in renal transplant recipients receiving basiliximab. Nephrol Dial Transplant 2010;25:1289-93.
63. Dagogo-Jack S. Pitfalls in the use of HbA(c) as a diagnostic test: the ethnic conundrum. Nat Rev Endocrinol 2010;6:589-93.
64. Chakkera HA, Weil EJ, Swanson CM, Dueck AC, Heilman RL, Reddy KS et al. Pretransplant risk score for new-onset diabetes after kidney transplantation. Diabetes Care 2011;34:2141-5.
65. Sharif A, Baboolal K. Risk factors for new-onset diabetes after kidney transplantation. Nature Reviews 2010;6:415-23.
66. Moghissi ES, Korytkowski MT, DiNardo M, Einhorn D, Heilman R, Hirsch IB et al. American Association of Clinical Endocrinologists and American Diabetes Association consensus statement on inpatient glycemic control. Endocr Pract 2009;15:353-69.
67. Standards of medical care in diabetes - 2012. Diabetes care 2012;35(Suppl 1):S11-63.
68. Umpierrez GE, Hellman R, Korytkowski MT, Kosiborod M, Maynard GA, Montori VM et al. Management of hyperglycemia in hospitalized patients in non-critical care setting: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 2012;97:16-38.
69. Tewari S, Kathuria A, Meier-Kriesche HU, Lansang MC. Association between admission hyperglycemia and length of stay after renal transplantation. Endocr Pract 2010;16:805-9.
70. Amnion JB, Sigakis M, Englesbe MJ, O'Reilly M, Pelletier SJ. Effect of intraoperative hyperglycemia during liver transplantation. J Surg Res 2007;140:227-33. (Pubitemid 46726378)
71. Park C, Hsu C, Neelakanta G, Nourmand H, Braunfeld M, Wray C et al. Severe intraoperative hyperglycemia is independently associated with surgical site infection after liver transplantation. Transplantation 2009;87:1031-6.
72. Wallia A, Parikh ND, O'Shea-Mahler E, Schmidt K, DeSantis AJ, Tian L et al. Glycemic control by a glucose management service and infection rates after liver transplantation. Endocr Pract 2011;17:546-51.
73. Chakkera HA, Knowler WC, Devarapalli Y, Weil EJ, Heilman RL, Dueck A et al. Relationship between inpatient hyperglycemia and insulin treatment after kidney transplantation and future new onset diabetes mellitus. Clin J Am Soc Nephrol 2010;5:1669-75.
74. Pham PT, Pham PC. Assessing the risk of post-transplantation diabetes mellitus with an oral glucose tolerance test. Nat Clin Pract Nephrol 2008;4.600-1.
75. Haidinger M, Werzowa J, Voigt HC, Pleiner J, Sterner G, Hecking M et al. A randomized, placebo-controlled, double-blind, prospective trial to evaluate the effect of vildagliptin in new-onset diabetes mellitus after kidney transplantation. Trials 2010;11:91.
76. Villanueva G, Baldwin D. Rosiglitazone therapy of posttransplant diabetes mellitus. Transplantation 2005;80:1402-5. (Pubitemid 41803620)
77. Goldberg PA. Comprehensive management of posttransplant diabetes mellitus: from intensive care to home care. Endocrinol Metab Clin North Am 2007;36:907-22; viii.
78. Luan FL, Steffick DE, Gadegbeku C, Norman SP, Wolfe R, Ojo AO. Graft and patient survival in kidney transplant recipients selected for de novo steroid-free maintenance immunosuppression. Am J Transplant 2009;9:160-8.
79. Vincenti F, Schena FP, Paraskevas S, Hauser IA, Walker RG, Grinyo J. A randomized, multicenter study of steroid avoidance, early steroid withdrawal or standard steroid therapy in kidney transplant recipients. Am J Transplant 2008;8:307-16.
80. Boudjema K, Camus C, Sahba F, Calmus Y, Salame E, Pageaux G et al. Reduced-dose tacrolimus with mycophenolate mofetil vs. standard-dose tacrolimus in liver transplantation: a randomized study. Am J Transplant 2011;11:965-76.
81. Dumortier J, Bernard S, Bouffard Y, Boillot O. Conversion from tacrolimus to cyclosporine in liver transplanted patients with diabetes mellitus. Liver Transpl 2006;12:659-64.
82. Ghisdal L, Bouchta NB, Broeders N, Crenier L, Hoang AD, Abramowicz D et al. Conversion from tacrolimus to cyclosporine A for new-onset diabetes after transplantation: a single-centre experience in renal transplanted patients and review of the literature. Transpl Int 2008;21:146-51.
83. Lorho R, Hardwigsen J, Dumortier J, Pageaux GP, Durand F, Bizollon T et al. Regression of new-onset diabetes mellitus after conversion from tacrolimus to cyclosporine in liver transplant patients: results of a pilot study. Clin Res Hepatol Gastroenterol 2011;35:482-8.
84. Lemahieu WP, Hermann M, Asberg A, Verbeke K, Holdaas H, Vanrenterghem Y et al. Combined therapy with atorvastatin and calcineurin inhibitors: no interactions with tacrolimus. Am J Transplant 2005;5:2236-43. (Pubitemid 41648471)
85. Jardine AG, Gaston RS, Fellstrom BC, Holdaas H. Prevention of cardiovascular disease in adult recipients of kidney transplants. Lancet 2011;378:1419-27.
86. Kasiske BL, Zeier MG, Chapman JR, Craig JC, Ekberg H, Garvey CA et al. KDIGO clinical practice guideline for the care of kidney transplant recipients: a summary. Kidney Int 2010;77:299-311.
87. Kasiske BL, Vazquez MA, Harmon WE, Brown RS, Danovitch GM, Gaston RS et al. Recommendations for the outpatient surveillance of renal transplant recipients. American Society of Transplantation. J Am Soc Nephrol 2000;11(Suppl 15):S1-86.
88. Cross NB, Webster AC, Masson P, O'Connell P J, Craig JC. Antihypertensives for kidney transplant recipients: systematic review and meta-analysis of randomized controlled trials. Transplantation 2009;88:7-18.
89. Fernandez-Fresnedo G, Escallada R, Rodrigo E, De Francisco AL, Cotorruelo JG, Sanz De Castro S et al. The risk of cardiovascular disease associated with proteinuria in renal transplant patients. Transplantation 2002;73:1345-8. (Pubitemid 34454288)
90. McLaren AJ, Fuggle SV, Welsh KI, Gray DW, Morris PJ. Chronic allograft failure in human renal transplantation: a multivariate risk factor analysis. Ann Surg 2000;232:98-103. (Pubitemid 30456556)
91. Pascual M, Curtis J, Delmonico FL, Farrell ML, Williams WW Jr, Kalil R et al. A prospective, randomized clinical trial of cyclosporine reduction in stable patients greater than 12 months after renal transplantation. Transplantation 2003;75:1501-5. (Pubitemid 36597285)
92. Johnson RW, Kreis H, Oberbauer R, Brattstrom C, Claesson K, Eris J. Sirolimus allows early cyclosporine withdrawal in renal transplantation resulting in improved renal function and lower blood pressure. Transplantation 2001;72:777-86. (Pubitemid 32879845)
93. Velosa JA, Larson TS, Gloor JM, Stegall MD. Cyclosporine elimination in the presence of TOR inhibitors: effects on renal function, acute rejection, and safety. Am J Kidney Dis 2001;38:S3-S10. (Pubitemid 32916883)
94. Duerr M, Glander P, Diekmann F, Dragun D, Neumayer HH, Budde K. Increased incidence of angioedema with ACE inhibitors in combination with mTOR inhibitors in kidney transplant recipients. Clin J Am Soc Nephrol 2010;5:703-8.
95. Iida S, Ishida H, Tokumoto T, Omoto K, Shirakawa H, Shimizu T et al. New-onset diabetes after transplantation in tacrolimus-treated, living kidney transplantation: long-term impact and utility of the pretransplant OGTT. Int Urol Nephrol 2010;42:935-45.
96. Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002; 346:393-403. (Pubitemid 34437694)
97. Pour OR, Dagogo-Jack S. Prediabetes as a therapeutic target. Clinical chemistry 2011;57:215-20.
98. Vincenti F, Friman S, Scheuermann E, Rostaing L, Jenssen T, Campistol JM et al. Results of an international, randomized trial comparing glucose metabolism disorders and outcome with cyclosporine versus tacrolimus. Am J Transplant 2007;7:1506-14. (Pubitemid 46776239)
99. Cole EH, Johnston O, Rose CL, Gill JS. Impact of acute rejection and new-onset diabetes on long-term transplant graft and patient survival. Clin J Am Soc Nephrol 2008;3:814-21.
100. Shah T, Kasravi A, Huang E, Hayashi R, Young B, Cho YW et al. Risk factors for development of new-onset diabetes mellitus after kidney transplantation. Transplantation 2006;82:1673-6. (Pubitemid 46035650)